Subscribe

Gene Therapy Market is projected to grow at an annualized rate of 45%, till 2030

Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline … Read More

Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMA® (AveXis) and ZYNTEGLO™ (bluebird bio). Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials that are anticipated to enter the market over the next 5-10 years.

The USD 11.6 billion (by 2030) financial opportunity within the Gene Therapy Market has been analyzed across the following segments:     

Key therapeutic areas

  • Autoimmune disorders
  • Cardiovascular diseases
  • Genetic disorders
  • Hematological disorders
  • Metabolic disorders
  • Ophthalmic disorders
  • Oncological disorders
  • Others

Type of vector

  • Adeno associated virus
  • Adenovirus
  • Herpes simplex virus type 1
  • Lentivirus
  • Plasmid DNA
  • Retrovirus
  • Vaccinia Virus

Type of therapy

  • Ex vivo
  • In vivo

Type of gene modification

  • Gene augmentation
  • Immunotherapy
  • Oncolytic therapy
  • Others

Route of administration

  • Intraarticular
  • Intracerebellar
  • Intramuscular
  • Intradermal
  • Intravenous
  • Intravitreal
  • Intravesical
  • Subretinal
  • Others

Key geographical regions

  • North America
  • Europe
  • Asia-Pacific

Get Detailed Sample Report: https://www.rootsanalysis.com/reports/268/request-sample.html

The Gene Therapy Market (3rd Edition), 2019-2030 report features the following companies, which we identified to be key players in this domain:

  • Advantagene
  • Advaxis
  • BioMarin
  • bluebird bio
  • FKD Therapies
  • Freeline Therapeutics
  • GenSight Biologics
  • Gradalis
  • Inovio Pharmaceuticals
  • Marsala Biotech
  • Orchard Therapeutics
  • Pfizer
  • Sarepta Therapeutics
  • Spark Therapeutics
  • Tocagen
  • Transgene
  • uniQure Biopharma
  • VBL Therapeutics
  • ViroMed

Table of Contents

  1. Preface
  2. Executive Summary
  3. Introduction
  4. Gene Delivery Vectors
  5. Regulatory Landscape and Reimbursement Scenario
  6. Competitive Landscape
  7. Marketed Gene Therapies
  8. Key Commercialization Strategies
  9. Late Stage (Phase II/III and Above) Gene Therapies
  10. Emerging Technologies
  11. Promising Therapeutics Areas
  12. Patent Analysis
  13. Mergers and Acquisitions
  14. Funding and Investment Analysis
  15. Cost Price Analysis
  16. Big Pharma Players: Analysis of Gene Therapy Related Initiatives
  17. Market Forecast and Opportunity Analysis
  18. Vector Manufacturing
  19. Case Study: Gene Therapy Supply Chain
  20. Conclusion
  21. Interview Transcripts
  22. Appendix 1: Tabulated Data
  23. Appendix 2: List of Companies and Organizations

Request for Customization:

https://www.rootsanalysis.com/reports/268/request-customization.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Author: admin